Who Paid My Doc
Jung Kim
Pain Medicine New York, NY Medical Doctor
NPI 1649414509 CMS profile 119930
1000 10Th Ave, New York, NY 10019
General payments
$9,417
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jung Kim of New York, NY is reported in the CMS Open Payments database as having received $9,417 across 37 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 79th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $710 | 10 | |
| 2024 | General | $5,894 | 7 | |
| 2023 | General | $798 | 5 | |
| 2022 | General | $1,513 | 8 | |
| 2021 | General | $27 | 2 | |
| 2020 | General | $32 | 2 | |
| 2019 | General | $442 | 3 |
Beside peers
- Jung Kim
- Pain Medicine median
- Middle half of Pain Medicine
- National median
In program year 2025, general payments to Jung Kim were reported at $710. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.
Show as a table
| Year | Jung Kim | Pain Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $442 | $498 | $126–$1,682 | $163 |
| 2020 | $32 | $284 | $80–$910 | $114 |
| 2021 | $27 | $399 | $112–$1,219 | $132 |
| 2022 | $1,513 | $455 | $137–$1,484 | $149 |
| 2023 | $798 | $484 | $128–$1,495 | $160 |
| 2024 | $5,894 | $498 | $131–$1,540 | $164 |
| 2025 | $710 | $458 | $124–$1,401 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 40 drugsPart D claims
3,225
Drug cost
$232,213
Branded share of claims
25.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Percocet Oxycodone Hcl/Acetaminophen | Brand | 19 | $68,591 | |
| Oxycontin Oxycodone Hcl | Brand | 57 | $24,640 | |
| Diclofenac Sodium | Generic | 104 | $23,508 | |
| Belbuca Buprenorphine Hcl | Brand | 16 | $16,604 | |
| Lyrica Pregabalin | Brand | 12 | $14,005 | |
| Roxicodone Oxycodone Hcl | Brand | 15 | $13,534 | |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | Brand | 394 | $9,012 | |
| Fentanyl | Generic | 68 | $7,446 | |
| Pregabalin | Generic | 251 | $6,356 | |
| Oxycodone Hcl | Generic | 284 | $5,647 |
The 10 drugs with the highest cost, of 40 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 58 billing codesPaid by Medicare
$283,438
Medicare patients
384
Services billed
3,709
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 75% | |
| Diabetes | 36% | |
| Ischemic heart disease | 35% | |
| Depression | 29% | |
| Osteoporosis | 25% | |
| Chronic kidney disease | 23% | |
| COPD | 18% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, methylprednisolone acetate, 40 mg J1030 | Office | 72 | 122 | $594 |
| Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml Q9965 | Office | 162 | 388 | $475 |
| Injection, dexamethasone sodium phosphate, 1 mg J1100 | Office | 50 | 621 | $55 |
| Injection, methylprednisolone acetate, 1 mg J1010 | Office | 136 | 309 | $31 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
37 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Pain Medicine in New York
Practitioners in the same specialty and state, ranked by reported value.
All Pain Medicine
Everyone recorded under this specialty, nationwide.
Doctors in New York
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.